Mike - I'll try to answer your question later

Mike -

I'll try to answer your question later this weekend. For now, here's some dot connecting and why personalized medicine is critical and what's makes companies like THI attractive.

This has been all over the news the last couple of days...

Tumours shrunk 'dramatically' in 11 days - 10 March 2016

"The drugs were lapatinib and trastuzumab , which is more widely known as Herceptin . They both target HER2 - a protein that fuels the growth of some women's breast cancers."

" Breast cancer is now thought of as at least ten separate diseases, each with a different cause, life expectancy and needing a different treatment.
Matching the specific errors in a tumour to targeted drugs is considered the future of cancer medicine."

http://www.bbc.com/news/health-35775314

FDA-Approved Drugs with Targets that are Measured on the
TheraLink® Assay for Breast Cancer

Ado-trastuzumab emtansine (Kadcyla®) - HER2 Lapatinib (Tykerb®) - EGFR/HER2
Afatinib (Gilotrif®) EGFR, HER2, HER3 Levatinib (Lenvima®) - VEGFR2 (Flk1), FGFRs)
Alfibercept (Eylea®) - VEGF-A, PIGF Panitumumab (Vectibix®) EGFR
Ataxinib (Inlyta®) - VEGFR2 (Flk1) Pertuzumab (Perjeta®) - HER3
Bevacizumab (Avastin®) - VEGF Ponatinib (Iclusig®) - Src, FGFR, VEGFR
Bosutinib (Bosulif®) - Src Ramucirumab (Cyramza®) - VEGFR2 (Flk1)
Carbozantinib (Cometriq®) - Met, VEGFR2 (Flk1) Regorafenib (Stivarga®) - VEGFR2 (Flk1), FGFRs
Ceritinib (Zykadia®) -Alk, IGF-1R Ruxolitinib (Jakafi®) - Jak2
Cetuximab (Erbitux®) - EGFR Sirolimus (Rapamune®) - mTOR
Crizotinib (Xalkori®) - Alk, Met Sorafenib (Nexavar®) - VEGFR2 (Flk1)
Dasatinib (Sprycel®) - Src Sunitinib (Sutent®) - VEGFR2 (Flk1)
Enzalutamide (Xtandi®) Androgen Receptor Temsirolimus (Torisel®) - mTOR
Erlotinib (Tarceva®) - EGFR Trametinib (Mekinist®) - Mek 1/2
Everolimus (Afinitor®) - mTOR Trastuzumab (Herceptin®) - HER2
Gefitinib (Iressa®) - EGFR Vandetanib (Caprelsa®) - EGFR


http://www.theranosticshealth.com/wp-content/...-Sheet.pdf